natural glp-1 receptor agonist Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Frontiers | GLP-1 receptor agonist
Description
GI adverse events with orforglipron were predominantly mild to moderate in severity and occurred most frequently during the dose-escalation period
Hypoglycemia is an insulin risk, not typically a GLP-1 risk
Springer reference
10.1186/1471-2202-13-33 [DOI] [PMC free article] [PubMed] [Google Scholar] Irwin M
In another phase II trial with 52 people with clinical evidence of NASH, liraglutide 1.8 mg treatment led to histological improvement of NASH [79]
What is the pipeline for future medications for obesity
